[go: up one dir, main page]

WO2014060941A3 - Compositions d'agents neuroprotecteurs et procédés correspondants destinés au traitement de maladies neurologiques et neurodégénératives - Google Patents

Compositions d'agents neuroprotecteurs et procédés correspondants destinés au traitement de maladies neurologiques et neurodégénératives Download PDF

Info

Publication number
WO2014060941A3
WO2014060941A3 PCT/IB2013/059356 IB2013059356W WO2014060941A3 WO 2014060941 A3 WO2014060941 A3 WO 2014060941A3 IB 2013059356 W IB2013059356 W IB 2013059356W WO 2014060941 A3 WO2014060941 A3 WO 2014060941A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
compositions
disorders
neurological
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2013/059356
Other languages
English (en)
Other versions
WO2014060941A2 (fr
Inventor
Mahesh Kandula
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2014060941A2 publication Critical patent/WO2014060941A2/fr
Publication of WO2014060941A3 publication Critical patent/WO2014060941A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés de formule (I) ou leurs sels pharmaceutiquement acceptables, ainsi que leurs polymorphes, solvates, énantiomères, stéréoisomères et hydrates. La présente invention concerne également des compositions pharmaceutiques comprenant une quantité efficace de composés de formule (I); et des méthodes de traitement de maladies neurodégénératives et neurologiques. Ces compositions peuvent être formulées pour administration par voie orale, buccale, rectale, topique, transdermique, transmuqueuse, intraveineuse, parentérale, ou bien sous forme de sirop ou sous forme injectable. Lesdites compositions peuvent être utilisées pour traiter les crises d'épilepsie, la maladie de Huntington, les spasmes, les maladies mentales, les troubles mentaux, la schizophrénie, la dépression, le stress, le trouble bipolaire, la maladie d'Alzheimer, l'anxiété, le THADA, la démence, les troubles de l'humeur, l'ESPT, l'épilepsie, l'insomnie, la migraine, la psychose, les TOC, l'autisme, les troubles anxieux, la manie, la démence et les troubles cognitifs.
PCT/IB2013/059356 2012-10-17 2013-10-15 Compositions d'agents neuroprotecteurs et procédés correspondants destinés au traitement de maladies neurologiques et neurodégénératives Ceased WO2014060941A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN4324CH2012 2012-10-17
IN4324/CHE/2012 2012-10-17

Publications (2)

Publication Number Publication Date
WO2014060941A2 WO2014060941A2 (fr) 2014-04-24
WO2014060941A3 true WO2014060941A3 (fr) 2014-07-10

Family

ID=50488841

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/059356 Ceased WO2014060941A2 (fr) 2012-10-17 2013-10-15 Compositions d'agents neuroprotecteurs et procédés correspondants destinés au traitement de maladies neurologiques et neurodégénératives

Country Status (1)

Country Link
WO (1) WO2014060941A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0136693A2 (fr) * 1983-10-03 1985-04-10 Takeda Chemical Industries, Ltd. Préparation de dérivés de la cytidine
EP0188647A1 (fr) * 1985-01-24 1986-07-30 NEOPHARMED S.p.A. Dérivés acylés de cytidine-diphosphate-choline, procédé pour leur préparation et leur usage thérapeutique
WO2003072067A2 (fr) * 2002-02-27 2003-09-04 Inspire Pharmaceuticals, Inc. Compositions et procedes de traitement de maladies des tissus epitheliaux et retiniens
WO2003099840A1 (fr) * 2002-05-24 2003-12-04 Isis Pharmaceuticals, Inc. Oligonucleotides a unites nucleosidiques modifiees

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0136693A2 (fr) * 1983-10-03 1985-04-10 Takeda Chemical Industries, Ltd. Préparation de dérivés de la cytidine
EP0188647A1 (fr) * 1985-01-24 1986-07-30 NEOPHARMED S.p.A. Dérivés acylés de cytidine-diphosphate-choline, procédé pour leur préparation et leur usage thérapeutique
WO2003072067A2 (fr) * 2002-02-27 2003-09-04 Inspire Pharmaceuticals, Inc. Compositions et procedes de traitement de maladies des tissus epitheliaux et retiniens
WO2003099840A1 (fr) * 2002-05-24 2003-12-04 Isis Pharmaceuticals, Inc. Oligonucleotides a unites nucleosidiques modifiees

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PONTONI, GABRIELE ET AL.: "Studies on enzyme-substrate interactions of cholinephosphotransferase from rat liver", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 836, 11 September 1985 (1985-09-11), pages 222 - 232 *

Also Published As

Publication number Publication date
WO2014060941A2 (fr) 2014-04-24

Similar Documents

Publication Publication Date Title
HK1217486A1 (zh) 作爲β-分泌酶抑制剂的全氟化环丙基稠合的1，3-恶嗪-2-胺化合物以及其使用方法
WO2014087367A3 (fr) Compositions et procédés pour le traitement de maladies neurologiques et de leurs complications associées
PH12013501556A1 (en) IMIDAZO[5,1-f][1,2,4]TRIAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
MX366855B (es) Compuestos perfluorados de 5,6-dihidro-4h-1,3-oxazin-2-amina como inhibidores de beta-secretasa y metodos de uso.
CL2015000096A1 (es) Compuestos derivados de 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos, inhibidores de fosfodiestearasa 2 y/o 10; composicion farmaceutica; y su uso para prevencion o tratamiento de enfermedades del sistema nervioso, como deficiencia cognitiva, demencia, trastornos de ansiedad, enf. de alzheimer, enf. de parkinson, otros
MY162413A (en) Novel heterocyclic derivatives and their use in the treatment of neurological disorders
MX2020013099A (es) Compuestos heteroaromaticos y su uso como ligandos d1 de dopamina.
GEP20207149B (en) Allosteric modulators of nicotinic acetylcholine receptors
NZ605486A (en) Spiro-cyclic amine derivatives as s1p modulators
JO3569B1 (ar) مركبات بروبيل حلقي متحد مع ثيازين-2-أمين كمثبطات انزيم بيتا سكريتاز وطرق استخدامها
PH12015500883A1 (en) Heteroaromatic compounds as dopamide d1 ligands
HK1220325A1 (zh) 苯并咪唑衍生物及其用途
PH12016501863A1 (en) Heteroaromatic compounds and their use as dopamine d1 ligands
PH12016501993A1 (en) Heteroaromatic compounds and their use as dopamine d1 ligands
IN2014DN09826A (fr)
EA201690971A1 (ru) ПИРИДО[4,3-b]ПИРАЗИН-2-КАРБОКСАМИДЫ В КАЧЕСТВЕ НЕЙРОГЕННЫХ СРЕДСТВ ДЛЯ ЛЕЧЕНИЯ НЕЙРОДЕГЕНЕРАТИВНЫХ РАССТРОЙСТВ
FI3541784T3 (fi) Uudet atsetidiinijohdannaiset, jotka ovat hyödyllisiä kortikaalisen katekoliamiini-neurotransmission modulaattoreina
WO2014060941A3 (fr) Compositions d'agents neuroprotecteurs et procédés correspondants destinés au traitement de maladies neurologiques et neurodégénératives
WO2014057439A3 (fr) Compositions et procédés de traitement de maladies neurologiques et des complications associées
PH12014502780A1 (en) Azetidine and piperidine compounds useful as pde10 inhibitors
WO2014060925A3 (fr) Compositions et méthodes de traitement de maladies neurologiques et neurodégénératives
JP2016520641A5 (fr)
TH167610A (th) อนุพันธ์ 6-ไดฟลูออโรเมทิล-5, 6 ไดไฮโดร-2h-[1,4]ออกซาซิน-3-เอมีน

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 13847165

Country of ref document: EP

Kind code of ref document: A2